Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

8 Biotech Stocks to Watch After the Q2 Earnings Season

By Chris Lau, InvestorPlace Contributor

Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.

AMD Stock’s Post-Earnings Recovering Shows Investor Optimism

By Chris Lau, InvestorPlace Contributor

AMD stock barely fell after reporting lower revenue. Investors are optimistic about AMD's prospects over the next few years.

NIO Could Be Worth Betting on at Below $3

By Chris Lau, InvestorPlace Contributor

Bears locked on the weak July delivery numbers NIO posted. August delivery numbers will rise. Plus, a better earnings report is possible.

After Another Strong Quarter, Alibaba Stock Will Reward Long-Term Investors

By Chris Lau, InvestorPlace Contributor

Alibaba stock reported a strong quarter, as usual. Markets will not react in the short term but those accumulating BABA will be rewarded.

Investors Shouldn’t Worry About Canopy Growth Stock’s Weak Q1

By Chris Lau, InvestorPlace Contributor

CGC stock sank after its last quarterly earnings report. Its first-quarter report will not impress investors either.

Load More